

# Discovery and development of novel ULK1 inhibitor as a therapeutic drug for RAS-mutated cancers

TXINNO Bioscience Inc.



ONCOLOGY	Lead																		
Product Type	Chemical Product (Small Molecule)																		
Indication	KRAS mutated cancers (KRAS G12C/D/V/S, G13D, Q61H)																		
Target	ULK1 (Unc 51-like autophagy activating kinase), serine/threonine protein kinase																		
MoA (Mechanism of Action)	<ul style="list-style-type: none"> <li>• Anti-proliferative effect via ULK1 inhibition in nutrient-poor environments</li> <li>• Synergistic tumor growth inhibition via synthetic lethality in combination with RAS/MEK/MAPK pathway inhibitors</li> </ul>																		
Competitiveness	From Cortellis search (Jan, 2023)																		
	<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="background-color: #d9e1f2;">ULK1 inhibitor</th> <th style="background-color: #d9e1f2;">Organization</th> <th style="background-color: #d9e1f2;">Development Status</th> </tr> </thead> <tbody> <tr> <td>DCC-3116</td> <td>Deciphera pharmaceutical Inc.</td> <td>Phase I</td> </tr> <tr> <td>ENV-201</td> <td>Endeavor BioMedicines</td> <td>Preclinical</td> </tr> <tr> <td>MR-2088</td> <td>H. Lee Moffitt Cancer Center</td> <td>Preclinical</td> </tr> <tr> <td>SBP-7455</td> <td>Salk Institute (Originator)</td> <td>Preclinical</td> </tr> <tr> <td>ERAS-5</td> <td>Erasca Inc.</td> <td>Discovery</td> </tr> </tbody> </table>	ULK1 inhibitor	Organization	Development Status	DCC-3116	Deciphera pharmaceutical Inc.	Phase I	ENV-201	Endeavor BioMedicines	Preclinical	MR-2088	H. Lee Moffitt Cancer Center	Preclinical	SBP-7455	Salk Institute (Originator)	Preclinical	ERAS-5	Erasca Inc.	Discovery
	ULK1 inhibitor	Organization	Development Status																
	DCC-3116	Deciphera pharmaceutical Inc.	Phase I																
	ENV-201	Endeavor BioMedicines	Preclinical																
	MR-2088	H. Lee Moffitt Cancer Center	Preclinical																
SBP-7455	Salk Institute (Originator)	Preclinical																	
ERAS-5	Erasca Inc.	Discovery																	
Development Stage	Lead																		
Route of Administration	Per Oral (PO)																		